Overall market sentiment has been neutral on Cara Therapeutics Inc (CARA) stock lately. CARA receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With CARA Stock Today?
Cara Therapeutics Inc (CARA) stock is higher by 0.28% while the S&P 500 has fallen -0.29% as of 1:17 PM on Tuesday, Jul 7. CARA is higher by $0.05 from the previous closing price of $17.57 on volume of 123,348 shares. Over the past year the S&P 500 is up 6.54% while CARA has fallen -18.12%. CARA lost -$2.55 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Cara Therapeutics Inc click here.
More About Cara Therapeutics Inc
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
